Wall Street brokerages expect Intrexon Corp (NYSE:XON) to report sales of $48.79 million for the current quarter, Zacks reports. Four analysts have provided estimates for Intrexon’s earnings. The lowest sales estimate is $44.65 million and the highest is $51.91 million. Intrexon posted sales of $46.00 million during the same quarter last year, which would indicate a positive year over year growth rate of 6.1%. The business is scheduled to issue its next earnings report on Wednesday, March 7th.
On average, analysts expect that Intrexon will report full year sales of $48.79 million for the current fiscal year, with estimates ranging from $197.50 million to $206.11 million. For the next financial year, analysts anticipate that the business will report sales of $249.15 million per share, with estimates ranging from $217.00 million to $281.22 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that cover Intrexon.
Intrexon (NYSE:XON) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.02. Intrexon had a negative net margin of 66.88% and a negative return on equity of 18.68%.
Shares of Intrexon (XON) opened at $12.60 on Friday. The company has a market cap of $1,600.00, a P/E ratio of -11.25 and a beta of 1.40. Intrexon has a 52-week low of $10.26 and a 52-week high of $26.99. The company has a current ratio of 2.05, a quick ratio of 1.85 and a debt-to-equity ratio of 0.01.
In related news, CEO Randal J. Kirk acquired 1,000,000 shares of the company’s stock in a transaction on Friday, January 19th. The shares were acquired at an average cost of $12.50 per share, for a total transaction of $12,500,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. 55.10% of the stock is currently owned by company insiders.
Large investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in Intrexon by 3.4% during the 2nd quarter. Vanguard Group Inc. now owns 4,433,879 shares of the biotechnology company’s stock valued at $106,811,000 after acquiring an additional 147,517 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Intrexon by 5.6% during the 2nd quarter. Goldman Sachs Group Inc. now owns 152,576 shares of the biotechnology company’s stock worth $3,675,000 after purchasing an additional 8,148 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Intrexon by 493.1% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,258 shares of the biotechnology company’s stock worth $271,000 after purchasing an additional 11,854 shares during the period. Trellus Management Company LLC bought a new stake in shares of Intrexon during the 3rd quarter worth $475,000. Finally, Dynamic Technology Lab Private Ltd raised its stake in shares of Intrexon by 127.0% during the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 24,640 shares of the biotechnology company’s stock worth $468,000 after purchasing an additional 13,783 shares during the period. Institutional investors and hedge funds own 73.31% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “$48.79 Million in Sales Expected for Intrexon Corp (XON) This Quarter” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/09/48-79-million-in-sales-expected-for-intrexon-corp-xon-this-quarter-2.html.
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.